Attracting Investors and Shortening Development Times

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

CDMO Consolidation

How Far Should CDMO Network Consolidation Go?

Pharma's Almanac

Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Asia Manufacturing

APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

EU Public–Private

Europe’s Innovation Engine: How Public–Private Partnerships Are Transforming Biomedical Research

David Alvaro, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac